Go Pro
→ Feds Say Your Cash Isn’t Property—Can They Take It? (From Priority Gold) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$6.27
+3.7%		$7.82
$4.68
▼
$179.19
$3.44M-0.07196,962 shs5,861 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.00%-5.03%-6.92%-49.54%-95.04%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$6.27
+3.7%		$7.82
$4.68
▼
$179.19
$3.44M-0.07196,962 shs5,861 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.00%-5.03%-6.92%-49.54%-95.04%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
1.50
ReduceN/AN/A

Current Analyst Ratings Breakdown

Latest LOK, UAI, FOXT, and ARTL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2026
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/A($17.03) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$12.88M-$16.80N/AN/AN/AN/A-518.27%-194.29%11/17/2026 (Estimated)

Latest LOK, UAI, FOXT, and ARTL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$6.48-$0.89+$5.59-$8.01N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/A
3.00
3.00

Institutional Ownership

CompanyInstitutional Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.87%

Insider Ownership

CompanyInsider Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
3.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
5550,000530,000Not Optionable

Recent News About These Companies

Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/artelo-biosciences-present-h-c-130000468.html
Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Large Decrease in Short Interest
August 31, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30993534
Artelo Biosciences Announces Reverse Stock Split
August 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3351943/0/en/artelo-biosciences-announces-reverse-stock-split.html
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
August 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348379/0/en/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13.html
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
August 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/17/3346126/0/en/artelo-biosciences-receives-a-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-its-lead-investigational-drug-currently-in-two-phase-2-studies.html
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344440/0/en/artelo-biosciences-provides-business-update-and-reports-2026-second-quarter-financial-results.html
Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/artelo-announces-enrollment-of-first-patient-in-a-phase-2-clinical-trial-evaluating-art27-13-for-treatment-of-glaucoma-1036435662
Artelo Biosciences Announces Preclinical Data Supporting ART26.12 for Osteoarthritis Pain with Reduced Gastric Damage Compared with Naproxen
July 16, 2026  |  quiverquant.comQ
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
July 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/16/3328460/0/en/artelo-biosciences-announces-results-from-a-nonclinical-osteoarthritis-study-supporting-art26-12-as-a-potential-first-in-class-new-therapy-for-chronic-pain-conditions.html
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
July 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/14/3326870/0/en/artelo-biosciences-issues-reminder-to-shareholders-to-vote-in-advance-of-annual-meeting-on-july-17-2026.html
Artelo Biosciences Announces ART27.13 Data Suggest Potential Benefit for Neuropathic Pain in Cancer Patients
July 13, 2026  |  quiverquant.comQ
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
July 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/13/3326230/0/en/artelo-biosciences-announces-positive-results-with-art27-13-in-a-nonclinical-model-of-paclitaxel-induced-peripheral-neuropathy.html
Artelo Biosciences Adjourns and Reschedules 2025 Annual Meeting
July 10, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ARTL/pressreleases/36872953/artelo-biosciences-adjourns-and-reschedules-2025-annual-meeting/
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
July 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/01/3320611/0/en/artelo-biosciences-announces-new-data-supporting-art26-12-as-a-potential-first-in-class-therapy-for-chronic-pain-associated-with-spinal-cord-injury.html
Artelo Biosciences Reports Multi-Omics Findings Highlighting Linoleic Acid Link in ART26.12 FABP5 Inhibition
June 30, 2026  |  quiverquant.comQ
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319708/0/en/artelo-biosciences-presents-evidence-for-a-common-lipid-signaling-link-across-multiple-potential-indications-for-its-fabp5-inhibitor-platform-at-icrs-2026.html
Artelo Biosciences Reports Positive First-in-Human ART26.12 Safety and Pharmacokinetic Results, Advances AI-Enabled Biomarker Research
June 29, 2026  |  quiverquant.comQ
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026
June 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/29/3318967/0/en/artelo-biosciences-presents-clinical-and-biomarker-data-supportive-of-the-development-of-art26-12-and-follow-on-fabp5-inhibitors-at-icrs-2026.html
Artelo Biosciences Presents Promising Metabolite Profiling Data for Lead FABP Inhibitor ART26.12 at Medicinal Chemistry Conference
June 10, 2026  |  quiverquant.comQ
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success
June 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/10/3309607/0/en/artelo-biosciences-presents-art26-12-human-metabolite-data-demonstrating-favorable-drug-metabolism-characteristics-associated-with-clinical-development-success.html

Media Sentiment Over Time

Top Headlines

View All Headlines
Split image comparing a Home Depot store aisle with lumber to a Walmart store aisle with a shopping cart.
Walmart and Home Depot Earnings Show the K (Shaped Economy) Is Here to Stay
By Dan Schmidt | August 24, 2026
Broadcom logo displayed on a computer chip mounted on a circuit board in a data center setting.
Broadcom’s Earnings Test Comes With a Higher Bar After NVIDIA’s Blowout
By Leo Miller | August 31, 2026
Rubrik logo displayed on a wall in a data center hallway lined with illuminated server racks.
Rubrik’s AI Security Bet Could Power the Next Leg Higher
By Thomas Hughes | August 30, 2026
SQM logo displayed on a concrete wall, with a mining or evaporation pond site visible in the background.
Sociedad Química y Minera’s Lithium Boom Is Back, But Iodine Steals the Show
By Chris Markoch | August 20, 2026
Illuminated Fabrinet logo sign beside a fiber-optic transceiver module with green light strands and manufacturing equipment in background.
Fabrinet’s Sell-Off May Prove It Is One of AI’s Most Misunderstood Stocks
By Thomas Hughes | August 18, 2026
Artelo Biosciences stock logo

Artelo Biosciences NASDAQ:ARTL

$6.26 +0.23 (+3.73%)
As of 02:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas